Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/45832
DC FieldValueLanguage
dc.contributor.authorBehrend, Ellen N.en_US
dc.contributor.authorMelián Limiñana, Carlosen_US
dc.date.accessioned2018-11-22T12:57:01Z-
dc.date.available2018-11-22T12:57:01Z-
dc.date.issued2013en_US
dc.identifier.isbn9781118997093en_US
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/45832-
dc.description.abstractThis chapter discusses the pathogenesis, classical signs, diagnosis, and treatment for hyperadrenocorticism (HAC) in dogs. The clinical signs of HAC result from chronically elevated serum cortisol concentrations. More than 80% of dogs with HAC have pituitary-dependent disease due to an adrenocorticotropic hormone (ACTH)-secreting adenoma; approximately 80% originate in the adenohypophysis and 20% in the intermediate lobe. Older, small breed dogs are predisposed to spontaneous HAC. Tests for spontaneous HAC are divided into screening tests, meant to determine if HAC is present, and differentiating tests, designed to ascertain whether the disease is pituitary-or adrenal-based. Selegiline inhibits the enzyme monoamine oxidase B and, as a result, increases hypothalamic dopamine concentrations, which, in turn, inhibit ACTH secretion from the intermediate lobe of the pituitary. Selegiline is effective in at most 20% of cases of pituitary-dependent HAC.en_US
dc.languageengen_US
dc.relation.ispartofClinical Endocrinology of Companion Animalsen_US
dc.sourceClinical Endocrinology Of Companion Animals, p. 43-64, (2013)en_US
dc.subject310907 Patologíaen_US
dc.subject.otherTrilostane Treatmenten_US
dc.subject.otherCushings-Diseaseen_US
dc.titleHyperadrenocorticism in Dogsen_US
dc.typeinfo:eu-repo/semantics/bookParten_US
dc.typeBooken_US
dc.identifier.doi10.1002/9781118997093.ch5en_US
dc.identifier.scopus84913570250-
dc.identifier.isi000351666700006-
dc.contributor.authorscopusid7003550712-
dc.contributor.authorscopusid55220360000-
dc.description.lastpage64en_US
dc.description.firstpage43en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Capítulo de libroen_US
dc.contributor.daisngid295064-
dc.contributor.daisngid874233-
dc.description.numberofpages22en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Behrend, EN-
dc.contributor.wosstandardWOS:Melian, C-
dc.date.coverdateEnero 2013en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-VETen_US
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptDiabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Patología Animal, Producción Animal, Bromatología y Tecnología de Los Alimentos-
crisitem.author.orcid0000-0002-1496-5706-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameMelián Limiñana, Carlos-
Appears in Collections:Capítulo de libro
Show simple item record

SCOPUSTM   
Citations

3
checked on Apr 18, 2021

WEB OF SCIENCETM
Citations

4
checked on Feb 28, 2021

Page view(s)

25
checked on Apr 18, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.